Latest report by Bartu et al reflected the consequences of somatic exonic mutations of HNF1B along with its role in the pathogenesis of kidney tumours emphasizing HNF1B could act as oncogene in papillary renal cell carcinoma (reduced HNF1B was exhibited along elevated tumour grade with T stage) whereas it may behave as a tumour suppressor in CCRCC and CHRCC (no mutations was observed whilst promotor methylation was present).95 This evidence concerns the gene HNF1B and papillary renal cell carcinoma.